SCHEMBL4825992

SCHEMBL4825992

Sc1nc2cc(OCc3ccccc3)ccc2[nH]1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 2/20 0.54
ALOX5 P09917 1/20 0.51
KDM4E B2RXH2 1/20 0.51
ALDH1A1 P00352 1/20 0.51
CYP1A2 P05177 1/20 0.51
CYP2C9 P11712 1/20 0.51
HPGD P15428 1/20 0.51
SRD5A2 P31213 1/20 0.51
HSD17B10 Q99714 1/20 0.51
PDGFRB P09619 1/20 0.48
PDGFRA P16234 1/20 0.48
NPC1 O15118 2/20 0.48
RAB9A P51151 2/20 0.48
MAOA P21397 3/20 0.47
MAOB P27338 2/20 0.47
CTSV O60911 2/20 0.46
CTSL P07711 2/20 0.46
NSD2 O96028 1/20 0.45
AS3MT Q9HBK9 1/20 0.45
IP6K1 Q92551 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4825999 0.89 CYP3A4 (0.54) CYP3A4ALOX5KDM4EALDH1A1CYP1A2
SCHEMBL2131853 0.83 XDH (0.55) CYP3A4ALOX5KDM4EALDH1A1CYP1A2
SCHEMBL9529962 0.83 CYP3A4 (0.54) CYP3A4ALOX5KDM4EALDH1A1CYP1A2
SCHEMBL4470392 0.81 NPC1 (0.52) CYP3A4ALOX5KDM4EALDH1A1CYP1A2
SCHEMBL4466653 0.80 ALDH1A1 (0.61) CYP3A4ALOX5KDM4EALDH1A1CYP1A2
SCHEMBL917237 0.79 HSD17B10 (0.49) CYP3A4KDM4EALDH1A1HPGDHSD17B10
SCHEMBL17292670 0.78 HSD17B10 (0.47) CYP3A4KDM4EALDH1A1HPGDHSD17B10
SCHEMBL2131850 0.78 KDM4E (0.55) CYP3A4ALOX5KDM4EALDH1A1CYP1A2
SCHEMBL5579690 0.78 CHEK2 (0.59) ALOX5KDM4EALDH1A1CYP1A2HPGD
SCHEMBL7921440 0.78 CYP3A4 (0.48) CYP3A4ALOX5KDM4EALDH1A1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1627875-B1 METHOD FOR PRODUCING CYCLIC DIAMINE DERIVATIVE OR SALT THEREOF KOWA CO (JP) 2013-07-31 EP disclosed
US-7459552-B2 Method for producing cyclic diamine derivative or salt thereof KOWA CO., LTD. (JP) 2008-12-02 US disclosed
US-20060293519-A1 Method for producing cyclic diamine derivative or salt thereof KOWA CO., LTD. (JP) 2006-12-28 US disclosed
EP-1627875-A1 METHOD FOR PRODUCING CYCLIC DIAMINE DERIVATIVE OR SALT THEREOF Kowa Co., Ltd. (JP) 2006-02-22 EP disclosed
US-6969711-B2 Cyclic diamine compounds and medicine containing the same KOWA COMPANY, LTD. (JP) 2005-11-29 US disclosed
US-20040038987-A1 Novel cyclic diamine compounds and medicine containing the same KOWA COMPANY, LTD. (JP) 2004-02-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060293519-A1 Method for producing cyclic diamine derivative or salt thereof NNT, APRT, SAT1 CYP3A4 3701/4885ALOX5 4552/4885KDM4E 795/4885
US-20040038987-A1 Novel cyclic diamine compounds and medicine containing the same LCAT, ACAT2, ACAT1 CYP3A4 1883/4885ALOX5 1706/4885KDM4E 1460/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.